# Peraso Inc.: Form 10-Q for the period ended Sep 30, 2015

- Company: [Peraso Inc.](/companies/prso.md) (CIK 890394)
- Form: 10-Q
- Filed: 2015-11-06
- Accepted by EDGAR: Nov 6, 2015, 17:09 ET
- Period: 2015-09-30
- Accession: 0001104659-15-076753
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/890394/000110465915076753/a15-17909_110q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/890394/000110465915076753/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2015-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2015-07-01 to 2015-09-30 | $1.0m | us-gaap:SalesRevenueNet |
| Revenue | 9 months, 2015-01-01 to 2015-09-30 | $2.8m | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months, 2015-07-01 to 2015-09-30 | $793.0k | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2015-01-01 to 2015-09-30 | $1.6m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2015-07-01 to 2015-09-30 | $229.0k | us-gaap:GrossProfit |
| Gross profit | 9 months, 2015-01-01 to 2015-09-30 | $1.2m | us-gaap:GrossProfit |
| Research and development | 3 months, 2015-07-01 to 2015-09-30 | $8.8m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2015-01-01 to 2015-09-30 | $21.5m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2015-07-01 to 2015-09-30 | $1.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2015-01-01 to 2015-09-30 | $4.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2015-07-01 to 2015-09-30 | −$10.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2015-01-01 to 2015-09-30 | −$25.0m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2015-07-01 to 2015-09-30 | $13.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2015-01-01 to 2015-09-30 | $60.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2015-07-01 to 2015-09-30 | −$10.1m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Net income | 9 months, 2015-01-01 to 2015-09-30 | −$25.0m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Diluted EPS | 3 months, 2015-07-01 to 2015-09-30 | −$0.15 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months, 2015-01-01 to 2015-09-30 | −$0.41 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months, 2015-01-01 to 2015-09-30 | −$23.1m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 9 months, 2015-01-01 to 2015-09-30 | $369.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2015-09-30 | $1.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2015-09-30 | $26.2m | us-gaap:AssetsCurrent |
| Total assets | at 2015-09-30 | $53.3m | us-gaap:Assets |
| Current liabilities | at 2015-09-30 | $2.4m | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | at 2015-09-30 | $50.6m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 22,499 characters.

*This Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the accompanying condensed consolidated financial statements and notes included in this report. This Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which include, without limitation, statements about the market for our technology, our strategy, competition, expected financial performance and capital raising efforts, all information disclosed under Item 3 of this Part I, and other aspects of our business identified in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission on March 13, 2015 and in other reports that we file from time to time with the Securities and Exchange Commission. Any statements about our business, financial results, financial condition and operations contained in this Form 10-Q that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “expects,” “intends,” “plans,” “projects,” or similar expressions are intended to identify forward-looking statements. Our actual results could differ materially from those expressed or implied by these forward-looking statements as a result of various factors, including the risk factors described below in “Company Overview,” “Liquidity and Capital Resources; Changes in Financial Condition,” “Risk Factors” and elsewhere in this report and under Item 1A of our annual report on Form 10-K for the year ended December 31, 2014. We undertake no obligation to update publicly any forward-looking statements for any reason, except as required by law, even as new information becomes available or events occur in the future.*

### Company Overview

Our strategy and primary business objective is to become a fabless semiconductor company focused on the development and sale of integrated circuits, or ICs, for the high-speed networking, communications, storage and computing markets. Our solutions deliver time-to-market, performance, power, area and economic benefits for system original equipment manufacturers, or OEMs. We have developed two families of ICs under the Bandwidth Engine® and LineSpeed™ product names. Bandwidth Engine ICs combine our proprietary 1T-SRAM® high-density embedded memory, integrated macro functions and high-speed serial interface, or SerDes, I/O, with our intelligent access technology and a highly efficient interface protocol. The LineSpeed IC product line is comprised of non-memory, high-speed SerDes I/O devices with gearbox and retimer functionality, which convert lanes of data received on line cards or by optical modules into different configurations and/or ensure signal integrity. Certain SerDes products have been developed under a strategic development and marketing agreement with Credo Semiconductor Ltd., or Credo, to whom we have paid a total of $4.7 million for the development of these new products. The initial gross profits earned by us from the sale of Credo developed products will be primarily applied to reimbursing us for these development payments and a portion will be paid to Credo. Once a remaining $3.6 million of this amount has been reimbursed, all gross profits from the sale of the Credo-developed products worldwide will be shared equally by Credo and us.

Historically, our primary business was the design, development, marketing, sale and support of differentiated intellectual property, or IP, including embedded memory and high-speed parallel and SerDes I/O used in advanced systems-on-chips, or SoCs. Currently, we are focused on developing differentiated IP-rich IC products and are dedicating all our research and development, marketing and sales budget to these IC products.

Our future success and ability to achieve and maintain profitability will be dependent on the marketing and sales of our IC products into networking, communications and other markets requiring high-bandwidth memory access. We are currently supporting approximately 25 existing customers, with whom we have achieved over 70 design-wins, which reflects broadening acceptance of our products. We define a design win as the point at which a customer has made a commitment to build a board against the fixed schematic for his system, and this board will utilize our IC Products. We continue to actively pursue additional design wins for the use of our ICs in networking and communication equipment. Our design wins represent the potential for significant future revenues. With limited history to date, however, we cannot estimate how much revenue each design win is likely to generate, or how much revenue all of these (and future design wins) are likely to generate. For example, our first design wins from 2012 and 2013 are starting to ramp into production, and, while we cannot predict how steep these ramps might be, we expect our revenues from them to grow in successive periods over the next few years. Another factor limiting our ability to predict future revenue levels is that, although we have established initial pricing of our IC products ordered to date, longer-term volume prices will be subject to negotiations with our customers and may vary substantially from these initial prices.

### Sources of Revenue

*Product.* Product revenue is generally recognized at the time of shipment to our customers. An estimated allowance may be recorded, at the time of shipment, for future returns and other charges against revenue consistent with the terms of sale. IC product revenue and costs relating to sales made through distributors with rights of return and stock rotation are deferred until the distributors sell the product to end customers due to our inability to estimate future returns and credits to be issued. At the time of shipment to distributors, an account receivable for the selling price is recorded, as there is a legally enforceable right to receive payment, inventory is relieved, as legal title to the inventory is transferred upon shipment, and the associated deferred margin is recorded as deferred revenues in the condensed consolidated balance sheets. Revenues are recognized upon receiving notification from the distributors that products have been sold to end customers.

*Royalty.* Royalty revenue represents amounts earned under provisions in our memory licensing contracts that require our licensees to report royalties and make payments at a stated rate based on actual units manufactured or sold by licensees for products that include our memory IP. Our license agreements require the licensee to report the manufacture or sale of products that include our technology after the end of the quarter in which the sale or manufacture occurs, and we recognize royalties in the quarter in which we receive the licensee’s report. The timing and level of royalties are difficult to predict. They depend on the licensee’s ability to market, produce and sell products incorporating our technology.

*Licensing.* Licensing revenue, which is included in royalty and other revenue, consists of fees earned from license agreements, development services, and support and maintenance. Our licensing revenue consists primarily of fees for providing circuit design, layout and design verification and granting licenses to customers that embed our technology into their products. The vast majority of our contracts allow for milestone billing based on work performed. We currently have no active license agreements generating licensing revenue.

### Critical Accounting Policies and Estimates

The discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires us to make certain estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. On an ongoing basis we make these estimates based on our historical experience and on assumptions that we consider reasonable under the circumstances. Actual results may differ from these estimates, and reported results could differ under different assumptions or conditions. Our significant accounting policies and estimates are disclosed in Note 1 of the “Notes to Consolidated Financial Statements” in our Annual Report on Form 10-K for the year ended December 31, 2014. As of September 30, 2015, there have been no material changes to our significant accounting policies and estimates.

### Results of Operations

#### Net Revenue.

*(dollar amounts in thousands)*

|  | September 30, 2015 | 2014 | Change 2014 to 2015 |  |
| --- | ---: | ---: | ---: | ---: |
| Product — three months ended | $565 | $437 | $128 | 29% |
| Percentage of total net revenue | 55% | 38% |  |  |
| Product — nine months ended | $1,288 | $1,993 | $(705) | (35)% |
| Percentage of total net revenue | 46% | 47% |  |  |

Product revenue increased for the three months ended September 30, 2015 compared with the same period of 2014 primarily due to higher shipment volumes. The decrease in product revenue for the nine months ended September 30, 2015 compared with the same period in 2014 is primarily due to lower distributor sales revenue and lower shipment volumes. Additionally, product revenue for the first nine months of 2014 included a reversal of $0.4 million of sales return reserves, which had been recorded in prior periods.

*(dollar amounts in thousands)*

|  | September 30, 2015 | 2014 | Change 2014 to 2015 |  |
| --- | ---: | ---: | ---: | ---: |
| Royalty and other— three months ended | $457 | $716 | $(259) | (36)% |
| Percentage of total net revenue | 45% | 62% |  |  |
| Royalty and other — nine months ended | $1,504 | $2,241 | $(737) | (33)% |
| Percentage of total net revenue | 54% | 53% |  |  |

Royalty and other revenue include revenues generated from licensing agreements. Royalty and other revenue decreased primarily due to a decrease in shipment volumes by licensees whose products incorporate our licensed IP and a decrease in revenue recognized from residual licensing agreements entered into in prior years.

#### Cost of Net Revenue and Gross Profit.

*(dollar amounts in thousands)*

|  | September 30, 2015 | 2014 | Change 2014 to 2015 |  |
| --- | ---: | ---: | ---: | ---: |
| Cost of net revenue — three months ended | $793 | $447 | $346 | 77% |
| Percentage of total net revenue | 78% | 39% |  |  |
| Cost of net revenue — nine months ended | $1,593 | $2,046 | $(453) | (22)% |
| Percentage of total net revenue | 57% | 48% |  |  |

*(dollar amounts in thousands)*

|  | September 30, 2015 | 2014 | Change 2014 to 2015 |  |
| --- | ---: | ---: | ---: | ---: |
| Gross profit — three months ended | $229 | $706 | $(477) | (68)% |
| Percentage of total net revenue | 22% | 61% |  |  |
| Gross profit — nine months ended | $1,199 | $2,188 | $(989) | (45)% |
| Percentage of total net revenue | 43% | 52% |  |  |

Cost of net revenue is primarily comprised of direct and indirect costs related to the sale of IC products.

Cost of net revenue increased for the three months ended September 30, 2015 compared with the same period of 2014 primarily due to higher IC shipment volumes and a $0.2 million provision for slow moving inventory. The decrease in cost of net revenue for the nine months ended September 30, 2015 compared with the same period of 2014 was primarily due to lower IC shipment volumes, partially offset by the provision for slow moving inventory recorded in the third quarter of 2015.

Gross profit decreased for the three and nine months ended September 30, 2015, compared with the same periods of 2014, primarily due to the decrease in our total revenue.

#### Research and Development.

*(dollar amounts in thousands)*

|  | September 30, 2015 | 2014 | Change 2014 to 2015 |  |
| --- | ---: | ---: | ---: | ---: |
| Research and development — three months ended | $8,793 | $7,507 | $1,286 | 17% |
| Percentage of total net revenue | 860% | 651% |  |  |
| Research and development — nine months ended | $21,475 | $20,993 | $482 | 2% |
| Percentage of total net revenue | 769% | 496% |  |  |

Our research and development expenses include costs related to the development of our IC products and amortization of intangible assets. We expense research and development costs as they are incurred.

The increase for the three months ended September 30, 2015 compared with the same period in 2014 was primarily due to mask tooling and other fabrication costs partially offset by decreases in consulting and personnel expenses, intangible asset amortization, and stock-based compensation charges. The $0.5 million increase for the nine months ended September 30, 2015 compared with the same period in 2014 was primarily due to increased mask tooling and other fabrication costs and personnel expenses, partially offset by decreases in consulting expenses, stock-based compensation charges, intangible asset amortization and software license fees.

Research and development expenses are expected to fluctuate in absolute dollars in the coming quarters, primarily due to the timing of mask tooling costs and other fabrication costs related to next generation products.

Research and development expenses included stock-based compensation expense of $0.6 million and $0.8 million for the three months ended September 30, 2015 and 2014, respectively. Research and development expenses included stock-based compensation expense of $2.2 million and $2.7 million for the nine months ended September 30, 2015 and 2014, respectively.

#### Selling, General and Administrative.

*(dollar amounts in thousands)*

|  | September 30, 2015 | 2014 | Change 2014 to 2015 |  |
| --- | ---: | ---: | ---: | ---: |
| SG&A — three months ended | $1,547 | $1,689 | $(142) | (8)% |
| Percentage of total net revenue | 151% | 146% |  |  |
| SG&A — nine months ended | $4,711 | $4,976 | $(265) | (5)% |
| Percentage of total net revenue | 169% | 118% |  |  |

Selling, general and administrative expenses consist primarily of personnel and related overhead costs for sales, marketing, finance, human resources and general management.

The decrease for the three months ended September 30, 2015 compared with the same period in 2014 was primarily due to reduced consulting costs and stock-based compensation charges. The decrease for the nine months ended September 30, 2015 compared with the same period in 2014 was primarily due to a decrease in stock-based compensation charges. Additionally, the 2014 periods included a reduction of expense for the sale of a domain name.

Selling, general and administrative expenses included stock-based compensation expense of $0.2 million and $0.3 million for the three month periods ended September 30, 2015 and 2014, respectively. Selling, general and administrative expenses included stock-based compensation expense of $0.7 million and $0.9 million for the nine month periods ended September 30, 2015 and 2014, respectively.

#### Other Income, net.

*(dollar amounts in thousands)*

|  | September 30, 2015 | 2014 | Change 2014 to 2015 |  |
| --- | ---: | ---: | ---: | ---: |
| Other income, net — three months ended | $19 | $30 | $(11) | (37)% |
| Percentage of total net revenue | 2% | 3% |  |  |
| Other income, net — nine months ended | $71 | $115 | $(44) | (38)% |
| Percentage of total net revenue | 3% | 3% |  |  |

18

Other income, net primarily consisted of interest income on our investments as well as foreign currency transaction activity, partially offset by other non-operating items.

#### Income Tax Provision.

*(dollar amounts in thousands)*

|  | September 30, 2015 | 2014 | Change 2014 to 2015 |  |
| --- | ---: | ---: | ---: | ---: |
| Income tax provision — three months ended | $13 | $23 | $(10) | (43)% |
| Percentage of total net revenue | 1% | 2% |  |  |
| Income tax provision — nine months ended | $60 | $65 | $(5) | (8)% |
| Percentage of total net revenue | 2% | 2% |  |  |

The provision for the three and nine months ended September 30, 2015 and 2014 was primarily attributable to taxes on earnings of our foreign subsidiaries and branches. We believe that, based on the history of our operating losses and other factors, the weight of available evidence indicates that it is more likely than not that we will not be able to realize the benefit of our net operating losses, which are primarily generated in the United States. Accordingly, a full valuation reserve has been recorded against our net deferred tax assets.

### Liquidity and Capital Resources; Changes in Financial Condition

#### Cash Flows

As of September 30, 2015, we had cash, cash equivalents and short and long-term investments of $25.5 million and had total working capital of $23.8 million. Our primary capital requirements are to fund working capital, including development of our IC products, and any acquisitions that we make that require cash consideration or expenditures.

Net cash used in operating activities was $23.1 million for the first nine months of 2015, which primarily resulted from our net loss of $25.0 million and $1.8 million in the net reduction in assets and liabilities, partially offset by non-cash charges, including stock-based compensation expense of $2.9 million and depreciation and amortization expenses of $0.8 million. The changes in assets and liabilities primarily related to the timing of the collection of receivables from customers and payments to vendors and increase in inventory.

Net cash used in operating activities was $18.7 million for the nine months of 2014, which primarily resulted from a net loss of $23.7 million, partially offset by non-cash charges, including stock-based compensation expense of $3.6 million, depreciation and amortization expenses of $1.1 million and $0.3 million in the change in assets and liabilities. The changes in assets and liabilities primarily related to the timing of payments to vendors.

Net cash used in investing activities was $1.5 million for the first nine months of 2015, and included net amounts transferred from cash and cash equivalents to investments of $1.2 million, which did not impact our liquidity, and $0.4 million for purchases of fixed assets.

Net cash provided by investing activities was $16.8 million for the first nine months of 2014, and included net amounts transferred to cash and cash equivalents from investments of $17.1 million, which did not impact our liquidity, partially offset by $0.3 million for purchases of fixed assets.

Our proceeds from financing activities for the first nine months of 2015 of $23.1 million consisted primarily of net proceeds received from the sale of common stock through a public offering and proceeds from the exercise of stock options and purchases of common stock under our employee stock purchase plan.

Our financing activities in the first nine months of 2014 primarily consisted of proceeds from the exercise of stock options and purchases of common stock under our employee stock purchase plan.

Our future liquidity and capital requirements are expected to vary from quarter to quarter, depending on numerous factors, including:

- level of revenue;
- cost, timing and success of technology development efforts;
- inventory levels, timing of product shipments and length of billing and collection cycles;
- fabrication costs, including mask costs, of our ICs currently under development;
- variations in manufacturing yields, materials costs and other manufacturing risks;
- costs of acquiring other businesses and integrating the acquired operations; and
- profitability of our business.

We expect our cash expenditures to continue to exceed receipts for the foreseeable future as our revenues will not be sufficient to offset our operating expenses, which include significant research and development expenditures for the expansion and fabrication of our IC products. We intend to continue our current product and research and development activities, although total expenditures on a monthly and quarterly basis will vary, primarily based on need for additional mask costs and tapeouts. Because we do not expect positive cash flows from operations in the foreseeable future, we will need to obtain additional funds to continue operating at the current level of expenditures. There can be no assurance that such funding will be available to us on favorable terms, if at all. We have an effective shelf registration statement on file with the SEC to allow us to sell up to approximately $27 million of our securities from time to time prior to September 2017.

If we were to raise additional capital through sales of our equity securities, our stockholders would suffer dilution of their equity ownership. If we engage in debt financing, we may be required to accept terms that restrict our ability to incur additional indebtedness, prohibit us from paying dividends, repurchasing our stock or making investments, and force us to maintain specified liquidity or other ratios, any of which could harm our business, operating results and financial condition. If we need additional capital and cannot raise it on acceptable terms, we may not be able to, among other things:

- develop or enhance our products;
- continue to expand our product development and sales and marketing organizations;
- acquire complementary technologies, products or businesses;
- expand operations, in the United States or internationally;
- hire, train and retain employees; or
- respond to competitive pressures or unanticipated working capital requirements.

Our failure to do any of these things could seriously harm our ability to execute our business strategy and may force us to curtail our research and development plans or existing operations.

### Contractual Obligations

The impact that our contractual obligations as of September 30, 2015 are expected to have on our liquidity and cash flow in future periods is as follows (in thousands):

|  | Payment Due by Period Total | Less than 1 year | 1-3 years | 3-5 years | More than 5 years |
| --- | ---: | ---: | ---: | ---: | ---: |
| Operating leases | $3,749 | $794 | $1,499 | $1,456 | $— |
| Software licenses | 1,155 | 1,125 | 30 | — | — |
|  | $4,904 | $1,919 | $1,529 | $1,456 | $— |

As of September 30, 2015, our software licenses primarily related to computer-aided design software.

## Market risk

As filed, 1,022 characters.

Our investment portfolio consists of money market accounts, certificates of deposit, commercial paper, corporate debt, government-sponsored enterprise bonds and municipal bonds. The portfolio dollar-weighted average maturity of these investments is within 12 months. Our primary objective with this investment portfolio is to invest available cash while preserving principal and meeting liquidity needs. No single security should exceed 5% of the portfolio or $2.0 million at the time of purchase. In accordance with our investment policy, we place investments with high credit-quality issuers and limit the amount of credit exposure to any one issuer. These securities, which approximated $24.9 million as of September 30, 2015 and earned an average annual interest rate of approximately 0.3% during the first nine months of 2015, are subject to interest rate and credit risks. We do not have any investments denominated in foreign currencies, and, therefore, are not subject to foreign currency risk on such investments.

## Controls and procedures

As filed, 1,281 characters.

*Disclosure Controls and Procedures.* Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Because of inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934. Based on this evaluation, our management concluded that as of September 30, 2015, our disclosure controls and procedures were effective.

*Changes in Internal Control over Financial Reporting.* During the third quarter of 2015, there was no change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 443 characters.

We face many significant risks in our business, some of which are unknown to us and not presently foreseen. These risks could have a material adverse impact on our business, financial condition and results of operations in the future. We have disclosed a number of material risks under Item 1A of our annual report on Form 10-K for the year ended December 31, 2014, which we filed with the Securities and Exchange Commission on March 13, 2015.

Filed Nov 6, 2015.
Source: SEC EDGAR, the filing index for accession 0001104659-15-076753. Last ingested by Listed: Nov 14, 2026, 21:17 ET. No prices; not investment advice.
